scispace - formally typeset
M

Maria De Santis

Researcher at Humanitas University

Publications -  83
Citations -  3669

Maria De Santis is an academic researcher from Humanitas University. The author has contributed to research in topics: Population & Rheumatoid arthritis. The author has an hindex of 29, co-authored 83 publications receiving 2601 citations. Previous affiliations of Maria De Santis include University of Milan & Catholic University of the Sacred Heart.

Papers
More filters
Journal ArticleDOI

Mapping and predicting mortality from systemic sclerosis

Muriel Elhai, +70 more
TL;DR: Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality.
Journal ArticleDOI

Type III interferons disrupt the lung epithelial barrier upon viral recognition.

TL;DR: A strong rationale is provided for rethinking the pathophysiological role of IFN-λ and its possible use in clinical practice against endemic viruses, such as influenza virus as well as the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Journal ArticleDOI

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.

TL;DR: A scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoimmune/autoinflammatory conditions associated with the disease are presented.
Journal ArticleDOI

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.

François-Xavier Lescure, +297 more
TL;DR: In this article, the authors evaluated the safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical(requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.
Journal ArticleDOI

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

TL;DR: Anti-CD20 treatment has been well tolerated and SSc patients experienced an improvement of the skin score and of clinical symptoms and the clear fall in IL-6 levels could contribute to the skin fibrosis improvement, while the presence of B cells in the skin seems to be irrelevant with respect to the outcome.